<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175146</url>
  </required_header>
  <id_info>
    <org_study_id>CRC L-SBRT 15-01</org_study_id>
    <nct_id>NCT03175146</nct_id>
  </id_info>
  <brief_title>A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely</brief_title>
  <official_title>Stereotactic Body RadioTherapy (SBRT) for Oligo-metastatic Colo-rectal Cancer With Bio-marker Evaluation for Early Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will evaluate if &quot;curative intent&quot; SBRT can provide high response rates
      and clinically meaningful cancer control with acceptable toxicity specifically in patient
      with metastatic colorectal cancer (mCRC) who do not have surgical options and are no longer
      responding to systemic therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SBRT for Oligo-metastatic Colorectal cancer
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate within the treated liver lesion</measure>
    <time_frame>6 months</time_frame>
    <description>RECIST Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Any progression of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>From date of randomization up to 5 years</time_frame>
    <description>Grade 3 CTCAE events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From date of Randomization to Death or Progression or 5 years whichever comes first.</time_frame>
    <description>Fact - H quality of life instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>From date of randomization upto 5 years</time_frame>
    <description>Median survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization upto 5 years</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colonic Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Body Radiation Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>5 treatments given over 2 weeks</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed Colo-rectal Cancer

          -  1-3 Liver metastasis measurable on Computed Tomography (CT) or Magnetic Resonance
             Imaging (MRI)

          -  Surgically resected primary disease

          -  Technically/medically inoperable or patient declined surgery

          -  Progression or Stability after at least 1 Line of chemotherapy

          -  Adequate marrow function: Hb &gt; 80g/L, Platelets &gt; 100 x 109/L, White blood cell &gt; 2 x
             109/L

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Age &gt; 18 years

          -  Patient must sign study specific informed consent prior to study entry

        Exclusion Criteria:

          -  Prior liver radiation, or radiation in close proximity to planned treatment sites

          -  Prior invasive malignancy

          -  Severe, active co-morbidity

          -  Active hepatitis or Child Pugh Score B (9) or worse

          -  Pregnant or nursing women

          -  Extra hepatic disease: Any Bone/Any Brain, 2 or more Lung metastasis

          -  Life expectancy &lt; 6 mo from any cause

          -  Concurrent chemotherapy

          -  Response to prior chemotherapy with minimal measurable disease in liver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richie Sinha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richie Sinha, MD</last_name>
    <phone>403-476-2601</phone>
    <email>richie.sinha@ahs.ca</email>
  </overall_contact>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

